Shares of CARSGEN-B (02171) rose more than 4%, reaching HK$10.9 as of press time, up 4.21%, with a turnover of HK$14.0204 million.
On the news front, CARSGEN-B recently announced that the preliminary results of a clinical trial (CT041-CG4010, NCT06857786) conducted in China for Kailimei® (satricabtagene autoleucel injection, product code: CT041, a Claudin18.2-targeting autologous CAR-T cell therapy candidate) as consolidation treatment following adjuvant therapy for patients with Claudin18.2-positive gastric/gastroesophageal junction cancer after radical resection were presented as a poster at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting on Sunday, October 25, 2026, from 12:00 to 12:45 Central European Summer Time (CEST).
Previously, on June 22, 2026, CARSGEN-B received notification from the National Medical Products Administration (NMPA) approving the new drug application for its independently developed Claudin18.2 autologous humanized CAR-T cell therapy product — Kailimei® (satricabtagene autoleucel injection) — for the treatment of Claudin18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric/gastroesophageal junction adenocarcinoma that has failed at least second-line treatment.
It is reported that Kailimei® is the world's first approved CAR-T cell therapy product for the treatment of solid tumors.
Comments